Nascent Biotech, Inc. (NBIO) Stock
Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Nascent Biotech, Inc.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.
Nascent Biotech, Inc. (NBIO) stock trades at $0.00 with a market capitalization of $103330. The stock is valued at a price-to-earnings (P/E) ratio of -0.04, price-to-book of -0.36, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.13, and currently trades 100.0% below its 52-week high.
On profitability, Nascent Biotech, Inc. generates a return on equity (ROE) of 268.93% — well above the market average, a sign of a high-quality business, return on capital employed of 868.81%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.nascentbiotech.com